Aethlon Medical, Inc.
AEMD
NASDAQ·Healthcare·Medical - Devices
$1.82
▼ -5.70%
P/E
—
Mkt Cap
—
52-Wk Range
$1.67–$41.50
52-Week Range
$1.67 - $41.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 94.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary exosome and virus removal technology
- Clinical collaboration with University of Pittsburgh Medical Center Hillman Cancer Center
- First-mover advantage in hemopurification immunotherapy
- Unique circulatory system filtration approach
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of Hemopurifier through clinical trials and FDA approval pathway
Value
Valuation data unavailable
Momentum
Falling
-82.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AEMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of -$4.02 vs -$3.92 consensus (-2.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q1 27
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How AEMD stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related